MDS 2022 | PADOVA trial: prasinezumab in early Parkinson’s disease

Gennaro Pagano, MD, MSc, PhD, F. Hoffmann – La Roche Ltd, Basel, Switzerland, gives an update on the PADOVA trial (NCT04777331) that is evaluating the efficacy and safety of intravenous prasinezumab versus placebo in participants with early Parkinson’s disease (PD) who are on stable symptomatic PD medication. Following the PASADENA trial (NCT03100149), the PADOVA study will confirm its results before advancing to further phases. Differently from the PASADENA trial, where a continuous end-point was used, in the PADOVA trial time-to-event end-points were implemented. Preliminary results from the study are expected soon. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.